BMI1 and breast cancer: Furthermore, IL1β treatment could induce icd‐IL1R2 release in a time‐ and dose‐dependent manner in IL1R2‐overexpressing breast cancer cells (Figure 5B,C), and IL1R2 neutralizing antibody pretreatment reversed IL1β induced BMI1 upregulation in breast cancer cells (Figure 5D).